• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

1988 Fiscal Year Final Research Report Summary

Treatment of lung metastasis from renal cell carcinoma with lymphokine-activated killer cells and interleukin-2.

Research Project

Project/Area Number 62480336
Research Category

Grant-in-Aid for General Scientific Research (B)

Allocation TypeSingle-year Grants
Research Field Urology
Research InstitutionYamanashi Medical College

Principal Investigator

UENO Akira  Yamanashi Medical College, Dept. of Urology, 医学部, 教授 (30010193)

Co-Investigator(Kenkyū-buntansha) KOMATSU Hideki  Yamanashi Medical College, Dept. of Urology, 医学部, 助教授 (30167407)
TASAKA Kachio  Yamanashi Medical College, Dept. of Immunology, 医学部, 助教授 (40093265)
Project Period (FY) 1987 – 1988
Keywordsrenal cell carcinoma / lung metastasis / adoptive immunotherapy / lymphokine-activated killer cell
Research Abstract

The conditions to induce lymphokine-activated killer (LAK) cells were investigated at first. Concentrations of serum in culture media, 1, 2 and 5% had no effect on induced LAK activity. The best density of peripheral blood lymphocytes in culture bottle was 2x10^6/ml, and the most effective concentration of recombinant interleukin-2 (<@2r<@D2IL-2) to generate LAK cells was 3u/ml. Cytotoxicity against Daudi cell appeared on the second day of culture and reached a peak on the third day. There was no difference in induced LAK activity between standing and rolling culture.
One patient with lung metastasis from renal cell carcinoma was treated with LAK cells and <@2r<@D2IL-2. LAK cells and <@D2r@>D2IL-2 were administered 11 times during 14 months, the first 2 times intravenously and 9 times via bronchial artery. The total number of LAK cells injected was 16.1x10<@D19@>D1 cells. Induced LAK activities gradually decreased and reached minimum at 6th treatment. From the 6th treatment plasma exchange was performed the day before administration of LAK cells. Induced LAK activities recovered from the 7th treatment. Despite these treatments the size of the metastatic lesion gradually increased.

  • Research Products

    (8 results)

All Other

All Publications (8 results)

  • [Publications] Hideaki Iizuka: Yamanashi Medical Journal. 3. 97-103 (1988)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] 田坂捷雄: クリニカル ファーマシー. 15. 41-44 (1988)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] 薮崎昇: Yamanashi Medical Journal.

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] Hirofumi Naganuma: Acta neurochirurgica.

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] Hideaki Iizuka: "Sudy or lymphokine-activated killer (LAK) cells. I Improved LAK cell induction in vitro" Yamanashi Medical Journal. 3. 97-103 (1988)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Kachio Tasaka: "Tumor immunotherapy with LAK cells." Clinical Pharmacy. 4. 41-44 (1988)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Noboru Yabusaki: "Adoptive immunotherapy for lung metastasis from renal cell carcinoma." Yamanashi Medical Journal.

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Hirofumi Naganuma: "Complete remission of recurrent glioblastoma multiforme following infusions of lymphokine-activated killer cells. A case report" Acta Neurochirurgia.

    • Description
      「研究成果報告書概要(欧文)」より

URL: 

Published: 1990-03-20  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi